Chemiluminescence Immunoassay Analyzer Market Report 2024

The chemiluminescence immunoassay analyzers market size has grown strongly in recent years. It will grow from $5.31 billion in 2023 to $5.67 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to several factors, ethical considerations and regulatory frameworks, adoption of risk management strategies in healthcare settings, a shift towards patient-centered care models, integration of multiple diagnostic functionalities, and increasing emphasis on early detection of diseases.

The chemiluminescence immunoassay analyzers market size is expected to see strong growth in the next few years. It will grow to $7.42 billion in 2028 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to several factors, increasing demand for rapid and accurate results at the point of care, rising global healthcare spending, a focus on personalized treatment approaches, demographic shifts towards an aging population, and improved access to healthcare services worldwide. Major trends expected in the forecast period include sustainable analyzer technologies, integration of IT and data management solutions, government initiatives aimed at enhancing healthcare infrastructure, a continued focus on personalized treatment approaches, and ongoing advancements in detection sensitivity and automation capabilities.

The increasing prevalence of chronic diseases is expected to drive growth in the chemiluminescence immunoassay analyzer market in the coming years. Factors contributing to this rise include aging populations, unhealthy lifestyles, and advancements in medical care that extend the lifespan of individuals with acute conditions, thereby increasing the incidence of long-term health issues. Chemiluminescence immunoassay analyzers play a crucial role in managing chronic diseases by providing precise and sensitive detection of biomarkers, aiding in accurate diagnosis and monitoring of treatment effectiveness. For example, a report published by the American College of Cardiology in August 2022 projects significant increases in major cardiovascular risk factors in the United States from 2025 to 2060. Diabetes, dyslipidemia, hypertension, and obesity are all expected to rise substantially during this period, highlighting the growing demand for diagnostic tools in chronic disease management.

Leading companies in the chemiluminescence immunoassay analyzer market are focusing on developing advanced diagnostic technologies, such as automated analyzers, to enhance decision-making and analytical capabilities. Automated analyzers perform analytical processes automatically and are widely used in medical laboratories for efficient and accurate testing of samples. For instance, in July 2023, Fapon Biotech Inc., a China-based life sciences company, introduced the Shine i8000/9000 chemiluminescence immunoassay system. This high-speed, fully automated analyzer operates at an ultra-high throughput of 900 tests per hour, enabling partners to develop cutting-edge clinical diagnostic solutions. With initial results available in just 10 minutes, the system provides rapid insights crucial for time-sensitive situations. It boasts a rapid testing pace and high throughput capacity, efficiently managing large sample volumes while maintaining reliable accuracy, making it ideal for medium- to large-scale laboratories.

In July 2021, PerkinElmer Inc., a US-based provider of technology and service solutions, completed the acquisition of Immunodiagnostic Systems Holdings (IDS) for $155 million. This acquisition positions PerkinElmer to integrate its expertise and testing capabilities with IDS’ chemiluminescence products in areas such as endocrinology, autoimmunity, and infectious diseases. IDS, based in the UK, specializes in chemiluminescence immunoassay analyzers.

Major companies operating in the chemiluminescence immunoassay analyzer market are F. Hoffmann-La Roche AG, Abbott Laboratories Inc., Siemens Healthineers AG, Wiener Lab Group, PerkinElmer Inc., BioMérieux SA, Beckman Coulter Life Sciences, Tosoh Bioscience LLC, Sysmex Corporation, Bio-Rad Laboratories Inc., Shenzhen Mindray Bio-Medical Electronics Co. Ltd., DiaSorin SpA, Euroimmun AG, Autobio Diagnostics Co. Ltd., Maccura Biotechnology Co. Ltd., Luminex Corporation, Fujirebio Holdings Inc., Randox Laboratories Ltd., Shenzhen Yhlo Biotech Co. Ltd., Addcare Bio-Tech Co. Ltd., Inova Diagnostics, Immunodiagnostic Systems Holdings (IDS), Dynex Technologies Inc., Nanjing Poclight Biotechnology Co. Ltd.

North America was the largest region in the chemiluminescence immunoassay analyzers market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemiluminescence immunoassay analyzer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chemiluminescence immunoassay analyzer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chemiluminescence immunoassay (CLIA) analyzers are sophisticated laboratory instruments used to detect and measure various substances such as proteins, hormones, and drugs in samples, employing chemiluminescence and immunoassay techniques. They are extensively utilized in clinical laboratories for their precise and automated detection capabilities, particularly for high-sensitivity detection of hormones, proteins, antibodies, and infectious agents.

The main types of CLIA analyzers include fully automated and semi-automated models. Fully automated CLIA analyzers are advanced devices that utilize chemiluminescence to automatically measure and analyze specific molecules in biological samples with high sensitivity and accuracy. They employ technologies such as sequential injection, random access, and batch analysis. These analyzers find applications in oncology, endocrinology, hepatitis and retroviruses, cardiac markers, infectious diseases, bone and mineral disorders, autoimmune diseases, allergies, gastrointestinal (GI) stool testing, and drug discovery and development. They are used by hospitals, clinics, medical laboratories, and pharmaceutical companies.

The chemiluminescence immunoassay analyzers market research report is one of a series of new reports that provides chemiluminescence immunoassay analyzers market statistics, including chemiluminescence immunoassay analyzers industry global market size, regional shares, competitors with a chemiluminescence immunoassay analyzers market share, detailed chemiluminescence immunoassay analyzers market segments, market trends and opportunities, and any further data you may need to thrive in the chemiluminescence immunoassay analyzers industry. This chemiluminescence immunoassay analyzers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chemiluminescence immunoassay analyzer market consists of sales of pacifier thermometers, automated instrumentation, quality control materials, and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.